Classement en actions
#29599
Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in... Ulisse Biomed S.p.A. is an Italy-based biotechnology enterprise specializing in healthcare diagnostics. The company develops and markets a diverse range of innovative platforms and products designed for disease detection. Central to its offerings is the Sagitta platform, which encompasses specialized tests such as Ladymed/HPV Selfy for human papillomavirus screening, CoronaMelt for identifying SARS-CoV-2, and CoronaMelt Var for detecting and genotyping SARS-CoV-2 variants. Sagitta also provides UlisseFaster, a vital reagent used for the pre-treatment of biological samples, alongside various diagnostic tools for sexually transmitted infections and for detecting HPV associated with oropharyngeal cancers. Beyond Sagitta, Ulisse Biomed boasts the NanoHybrid platform, an advanced multi-modal biomolecule system that utilizes DNA/PNA technology to directly identify specific antibodies and protein analytes from serum or whole blood samples. Its portfolio is further enhanced by the Aptavir platform, dedicated to the development and manufacturing of synthetic nucleic acid molecules aimed at curtailing the infectiousness of pathogens. Established in 2015, Ulisse Biomed S.p.A. operates from its headquarters in Udine, Italy.
Prix de l'action
$0.93739396
Dernière synchronisation: 2026-01-08
Capitalisation boursière
$20.44M
Changement (1 jour)
0.60%
Échange Ulisse Biomed S.p.A. (UBM)
Revenus pour Ulisse Biomed S.p.A. (UBM)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Ulisse Biomed S.p.A., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Ulisse Biomed S.p.A. de 2026 à 2026
Revenus à la fin de chaque année
| Année |
Revenus |
Changez |
|
Pas assez de données pour les dates fournies. |
Revenus d’entreprises similaires ou concurrentes
| Entreprise |
Revenus |
Différence de revenus |
Pays |
|
|
$12.62B |
-
|
US
|
|
|
$6.02B |
-
|
NL
|
|
|
$15.70B |
-
|
AU
|
|
|
- |
-
|
CH
|
|
|
- |
-
|
KR
|
